Dobutamine During Major Abdominal Surgery

Launched by UNIVERSITY OF HAMBURG-EPPENDORF · May 22, 2025

Keywords

ClinConnect Summary

The PUSH-1 trial is a research study looking at whether a medication called dobutamine can be safely used in patients undergoing major abdominal surgeries. This medication is being tested to see if it can help support heart function during surgery, especially for patients who may be at risk of heart issues while under anesthesia. The study will take place at a single medical center and is not currently recruiting participants.

To be eligible for this trial, participants must be at least 18 years old and scheduled for planned major abdominal surgery that will last at least two hours. They will also need to have a monitor placed in their artery to check their blood pressure for medical reasons. However, people having emergency surgeries, organ transplant surgeries, or those with certain heart conditions will not be able to participate. If you join the study, you can expect to receive the dobutamine during your surgery and be monitored closely. This research could help doctors understand better ways to support patients' hearts during major operations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Consenting patients ≥18 years scheduled for elective major abdominal surgery under general anesthesia (expected surgery duration ≥ 120 minutes)
• • Planned continuous intraarterial blood pressure monitoring using an arterial catheter for clinical indications not related to the trial
• Exclusion Criteria:
• • Emergency surgery
• • Liver or kidney transplantation surgery
• • Status of post transplantation of kidney, liver, heart, or lung
• • Pregnancy
• • Heart rhythms other than sinus rhythm